Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COVID-19 Vaccine, mRNA
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
Details : Undisclosed
Product Name : Comirnaty
Product Type : Vaccine
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : COVID-19 Vaccine, mRNA
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Papillomavirus Quadrivalent Vaccine
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : National Institutes of Health | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Recombinant Human Papillomavirus Quadrivalent Vaccine
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : National Institutes of Health | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VEE DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Venezuelan Equine Encephalitis (VEE) vaccine is delivered with PharmaJet precision delivery, needle-free injection system resulted in humoral and cellular immune responses significant protection against disease and viremia.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 16, 2023
Lead Product(s) : VEE DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SCIB1,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Scancell
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : SCIB1,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Scancell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DTRA
Deal Size : $4.0 million
Deal Type : Agreement
Details : The funding will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DTRA
Deal Size : $4.0 million
Deal Type : Agreement
Lead Product(s) : SCOV1,SCOV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Scancell
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Covidity (SCOV1 and SCOV2 vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Product Name : Covidity
Product Type : Vaccine
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : SCOV1,SCOV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Scancell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DNA-Based Venezuelan Equine Encephalitis Virus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Military Health System Research Symposium
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Delivery of Venezuelan equine encephalitis DNA vaccine with PharmaJet Stratis® (Intramuscular – IM) or PharmaJet Tropis® (Intradermal – ID) Needle-free Injection System resulted in humoral and cellular immune responses significant protection agains...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : DNA-Based Venezuelan Equine Encephalitis Virus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Military Health System Research Symposium
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $0.8 million
Deal Type : Funding
Details : Phase II grant from the National Institutes of Health (NIH), to evaluate the immunogenicity of intradermal administration of human papillomavirus virus (HPV) vaccine using their Tropis intradermal (ID) Needle-free Injection System (NFIS).
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : HPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $0.8 million
Deal Type : Funding
Lead Product(s) : Fractional Inactivated Poliovirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : USAID
Deal Size : $1.5 million
Deal Type : Funding
Details : The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).
Product Name : fIPV
Product Type : Vaccine
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Fractional Inactivated Poliovirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : USAID
Deal Size : $1.5 million
Deal Type : Funding